Triptorelin

Generic Name: Triptorelin

Brand Names: Decapeptyl, Trelstar, Triptodur

Drug Type: Small Molecule

Chemical Formula: C_₆₄H_₈₂N_₁₈O_₁₃

CAS Number: 57773-63-4

Unique Ingredient Identifier: 9081Y98W2V

Background: Triptorelin is a synthetic decapeptide agonist analog of luteinizing hormone releasing hormone (LHRH). Possessing greater potency than endogenous LHRH, triptorelin reversibly represses gonadotropin secretion. After chronic, continuous administration, this agent effects sustained decreases in LH and FSH production and testicular and ovarian steroidogenesis. Serum testosterone concentrations may fall to levels typically observed in surgically castrated men.

Indication: Triptorelin is indicated for the palliative treatment of advanced prostate cancer.

Associated Conditions: Advanced Prostate Cancer

Associated Therapies: Controlled ovarian hyperstimulation therapy

Clinical Trials

Study To Assess Renewal Of Treatment In Patients Recently Diagnosed With Prostate Cancer

Completed

Conditions: Prostate Cancer

Interventions: Drug: triptorelin

First Posted Date: 2014-09-12

Last Posted Date: 2019-07-25

Lead Sponsor: Ipsen

Target Recruit Count: 368

Registration Number: NCT02238366

GnRHa Trigger in Asian Oocyte Donors- a Dose Finding Study

Not Applicable

Completed

Conditions: Normal Oocyte Donors

Interventions: Drug: Triptorelin

First Posted Date: 2014-08-05

Last Posted Date: 2017-02-06

Lead Sponsor: Vietnam National University

Target Recruit Count: 165

Registration Number: NCT02208986

Locations: 🇻🇳
My Duc Hospital, IVFMD, Ho Chi Minh City, Ho Chi Minh, Vietnam

Clomiphene Citrate Plus Gonadotropins and GnRH Antagonist Versus Flexible GnRH Antagonist Protocol Versus Microdose GnRH Agonist Protocol in Poor Responders Undergoing IVF

Phase 4

Conditions: IVF
GnRH Agonist
GnRH Antagonist
Poor Responders
Clomiphene Citrate

Interventions: Drug: Triptorelin plus daily FSH anh LH
Drug: Clomiphene citrate
Drug: Daily FSH and LH plus Cetrorelix

First Posted Date: 2014-07-28

Last Posted Date: 2014-07-28

Lead Sponsor: Bioroma

Target Recruit Count: 250

Registration Number: NCT02201914

Locations: 🇮🇹
Bioroma, Rome, Italy

Supportive Therapy in Androgen Deprivation Clinic in Improving Health Outcomes and Managing Side Effects in Patients With Prostate Cancer

Phase 2

Terminated

Conditions: Prostate Adenocarcinoma

Interventions: Drug: Goserelin Acetate
Behavioral: Behavioral Dietary Intervention
Other: Laboratory Biomarker Analysis
Other: Counseling
Other: Educational Intervention
Drug: Leuprolide Acetate
Other: Quality-of-Life Assessment
Behavioral: Exercise Intervention
Drug: Triptorelin Pamoate

First Posted Date: 2014-06-20

Last Posted Date: 2020-07-23

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 57

Registration Number: NCT02168062

Locations: 🇺🇸
University of California, San Francisco, San Francisco, California, United States

GnRH Agonist Triggering Supplemented With Hcg in Women With Poor Ovarian Response

Not Applicable

Conditions: Women With Poor Ovarian Response

Interventions: Drug: Ovitrel
Drug: Decapeptyl

First Posted Date: 2014-05-22

Last Posted Date: 2014-05-22

Lead Sponsor: Sheba Medical Center

Target Recruit Count: 60

Registration Number: NCT02144818

Locations: 🇮🇱
Sheba medical center, Ramat Gan, Israel

Anti-Mullerian Hormone (AMH) as Marker of Ovarian Reserve

Phase 2

Terminated

Conditions: Breast Cancer

Interventions: Drug: Triptorelin

First Posted Date: 2014-04-14

Last Posted Date: 2022-09-10

Lead Sponsor: Armando Santoro, MD

Target Recruit Count: 45

Registration Number: NCT02113553

Locations: 🇮🇹
Istituto Clinico Humanitas, Rozzano, Milan, Italy

MRI Substudy; Metabolic Changes Due to Iatrogenic Hypogonadism

Phase 4

Completed

Conditions: Hypogonadism
Fatty Liver
Metabolic Syndrome
Prostate Cancer

Interventions: Procedure: Orchiectomy
Drug: Triptorelin

First Posted Date: 2014-04-03

Last Posted Date: 2015-10-28

Lead Sponsor: Herlev Hospital

Target Recruit Count: 31

Registration Number: NCT02102646

Locations: 🇩🇰
Herlev Hospital, Herlev, Denmark

Long Acting FSH Plus Antagonist Versus Daily FSH Plus Antagonist Versus Short Agonist Protocol in Poor Responders Undergoing IVF

Phase 4

Conditions: Female Infertility
Poor Responder

Interventions: Drug: Long acting FSH and GnRH antagonist
Drug: Daily FSH and GnRH antagonist
Drug: Triptorelin and recombinant FSH

First Posted Date: 2014-02-25

Last Posted Date: 2014-02-25

Lead Sponsor: Bioroma

Target Recruit Count: 120

Registration Number: NCT02070198

Locations: 🇮🇹
Bioroma, Rome, Italy

GnRH Agonist Trigger and Modified Luteal Phase Support, Adding a Bolus of GnRHa at the Time of Implantation - a RCT

Phase 3

Completed

Conditions: Infertility

Interventions: Drug: Triptorelin 0.1mg

First Posted Date: 2014-02-04

Last Posted Date: 2017-07-21

Lead Sponsor: Centre Hospitalier Universitaire Ibn Rochd

Target Recruit Count: 328

Registration Number: NCT02053779

Locations: 🇩🇿
Ibn Rochd Infertility Centre, Constantine, Algeria

Repeated Injection of GnRH Agonist to Reduce Ovarian Hyperstimulation Syndrome

Not Applicable

Conditions: Infertility and at High Risk of OHSS

Interventions: Drug: triptorelin

First Posted Date: 2013-12-27

Last Posted Date: 2013-12-27

Lead Sponsor: Chenshiling

Target Recruit Count: 80

Registration Number: NCT02022241

Locations: 🇨🇳
Center for Reproductive Medicine, Department of Gynecology and Obstetrics, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy